Metastatic Pancreatic Ductal Adenocarcinoma Study
Status: Ongoing
About
A Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Metastatic Pancreatic Cancer (ASPIRE)
Details
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor: Panbela Therapeutics
NCT05254171
